New Delhi: The use of molnupiravir anti-virus drugs has a risk that must be warned, health officials say it underlines serious concerns about rampant, irrational and excessive drugs in the treatment of Covid-19.
“We have extensive discussions among experts and review any data available from three trials – one in 1,433 patients in the US; one stated before the time is stopped for business reasons and others ongoing.
There are 12 clinical trials listed on The Indian clinical registry, which starts or will start.
The last conclusion is that Molnupiravir has a certain risk that guarantees being cautious in its use.
Experts present at the meeting argue that there is a rampant and irrational use of pills.
Efforts must be made to limit their use As a deep danger exceeding the benefits claimed, “said the Director General of ICMR Balram Bhargava.
“Members in a unanimous voice agree that the drug does not deserve to be included in the National Covid Treatment Guidelines,” he added.
This is the second time in a week that the ICMR head has warned of drug use.
Last week, ICMR showed serious concerns with drug use in children, pregnant and lactating women.
See the use of rampant drugs, the government warns Molnupiravir
